UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 15, 2016**

FLAMEL TECHNOLOGIES S.A.

(Exact name of registrant as specified in its charter)

Republic of France	**000-28508**	**98-0639540**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Parc Club du Moulin à Vent **33, avenue du Docteur Georges Levy** **69200 Vénissieux France**	**Not Applicable**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **011 +33 472 78 34 34**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Other Events.

On November 16, 2016, Flamel Technologies S.A. (the "Company") intends to make a presentation at Jefferies 2016 Healthcare Conference in London, England. A copy of the Company's complete slide presentation to be used at the Conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company's presentation will be webcast live and can be accessed by visiting the Investor section of the Company's website at http://www.flamel.com/investors. A replay of the presentation, together with the complete slide presentation, will also be available and archived for at least 30 days on the website following the event.

The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1	Form of Slide Presentation of Flamel Technologies S.A. as of November 15, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FLAMEL TECHNOLOGIES S.A.

By: /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary

Date: November 15, 2016

Exhibit Index

99.1	Form of Slide Presentation of Flamel Technologies S.A. as of November 15, 2016.


FLAMEL
technologies

Company Highlights

Strong Financial Position	• Cash flow positive & strong balance sheet – NO DEBT • $149.7 million in cash & marketable securities at September 30, 2016
Phase III Trial	• Data for Micropump® applied to sodium oxybate expected 1H 2018 • Current market size in excess of $1 billion
Expanding Product Portfolio	• 3 branded hospital products with little competition • 4 products added through acquisition of FSC Pediatrics in Q1 2016
Platform Technologies	• Micropump® sodium oxybate • LiquiTime® for OTC and Rx • Trigger Lock™ hydromorphone • Medusa™ exenatide
Extensive IP	• Technology patent life extends to a minimum of 2025 • Product specific IP will extend patent life

Mission: Build a diversified specialty pharmaceutical company that controls 100% of its drug development and future

Corporate Transformation



Since 2013 Flamel received three NDA approvals, initiated Phase III trial for Micropump® sodium oxybate & transformed into a cash flow positive company

Becoming Avadel Pharmaceuticals plc

- ***Avadel Pharmaceuticals plc*** (NASDAQ: AVDL)
- "**A**d**VA**nced **DEL**ivery"
- Cross-border merger from France to Ireland effective January 1, 2017
- No changes to capital structure or share count

Avadel

2016 Expectations

- ✓ Launch Akovaz™ (Approved on 4/29/16)
- ✓ Integrate FSC Pediatrics and optimize sales territories
- ✓ Begin licensing discussions for Trigger Lock™ & Medusa™ platforms
- ✓ Commence registration & dosing for Phase III trial of Micropump® sodium oxybate by 2H 2016
- **Initiate development of UMD #4**
- **Generate total revenue of $133 - $143 million**

[1] UMD is Flamel's Unapproved Marketed Drugs Strategy, which takes unapproved drugs through the FDA approval process. These products are not protected by IP and are subject to generic filers.

Current Pipeline

Drug/ Technology	Indication	Proof of Concept	Phase III	Under Review	Approved
Unapproved Marketed Drug #4	Undisclosed	→			
Sodium oxybate/ Micropump®	Narcolepsy	→	→		
Hydromorphone / Trigger Lock™	Pain	→			
Exenatide/Medusa™	Diabetes	→			
Partnered Products					
LiquiTime®	Cough/Cold	→			

Phase III trial for Micropump® sodium oxybate initiated September 2016

No IP Protection IP Protection

Sodium Oxybate Market Opportunity

>~178,000 narcoleptic patients in U.S.*



Large untapped opportunity exists in narcolepsy patient population

Xyrem® FY 2016 sales expected to be $1.2 - $1.25 billion

* *GlobalData & JAZZ's 4Q'15 earnings call*

Micropump® Sodium Oxybate (FT218)

Studied in 40 healthy volunteers at 4.5 grams, 6 grams and 7.5 grams

Results showed:
Similar onset of action as Xyrem
Slightly lower Cmax than Xyrem
Similar blood levels at hours 7 - 8

Sodium Oxybate: Standard of care for treatment of excessive daytime sleepiness **(EDS) & cataplexy** for patients suffering from narcolepsy

Dosed twice nightly*
3 - 4.5 grams at bedtime
3 - 4.5 grams at 2.5 – 4 hrs later

FT218 has potential to eliminate 2nd dose & provide other patient benefits

* Xyrem prescribing information

Phase III Pivotal Trial - FT218

- Randomized, double-blind, placebo controlled efficacy study
- **264** patients
- **~50-60** clinical sites across U.S., Canada & Eastern Europe

- Patients will undergo screening period then be titrated to daily doses of **4.5 g, 6.0 g, 7.5 g and 9.0 g** FT218 or placebo
- **Patients on drug or placebo for 13 weeks**
- Overall timeline to complete enrollment: **~ 1 year**

Micropump® Overview

Robust platform technology utilizing microparticles for the extended/delayed release of drugs in GI tract

Tailored release profile solves dosing problems related to PK profiles and drugs with short half lives

Micropump 1st approved in 2006 in Coreg CR (carvedilol)

10 years – no generics

Applicable to wide variety of molecules

Patented through 2027 with product specific patents to extend protection

Trigger Lock™ Hydromorphone (FT227)



[1] IMS data [2] "America's Addiction to Opioids: Heroin and Prescription Drug Abuse" (National Institute on Drug Abuse, May 14, 2014)

LiquiTime® Overview

Licensed OTC rights to Perrigo in October 2015 – first two products:

- Ibuprofen
  - 12 hour profile developed for pain/fever
  - Regulatory pathway deemed high risk and high cost
- Guaifenesin
  - Successful pilot PK study reported in March 2015
  - Second PK study ongoing
  - Update anticipated in early 2017

LiquiTime for prescription products currently under feasibility

Medusa™ Exenatide (FT228)

Subcutaneous injection formulation of exenatide, a GLP-1 (glucagon-like peptide – 1) for treatment of Type 2 diabetes

Phase Ib Results

- 1 dose FT228 (140mcg) / week for 4 weeks in 12 type 2 diabetes mellitus patients
- PK data showed continuous release of exenatide over period of up to 14 days & RBA close to 100%
- PD data comparable to current marketed products Bydureon® & Victoza®
- Low incidence of prolonged GI side effects and mild injection site reactions
- **Actively seeking partnership / licensing deal for Medusa**

Market Opportunity

- GLP-1 products recorded **$3.9 billion* of sales:**
- **$2.5 million** for Victoza® (once a day liraglutide, Novo Nordisk)
- **$736 million** for Bydureon® (once-a-week exenatide, AstraZeneca)
- **$319 million** for Byetta® (twice-a-day exenatide, AstraZeneca)

*IMS – U.S. sales in 2015

Marketed Products

Éclat Portfolio Products

Bloxiverz® (neostigmine methylsulfate injection)

- Indication: Reverses neuromuscular blockades used in surgical procedures
- 1 of 3 approved versions; ~ 4 million vials sold annually in the U.S.*

Vazculep® (phenylephrine hydrochloride injection)

- Indication: Treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia
- Form: 1 mL single use vials, 5 mL and 10 mL
  - 1mL vial – **5.7** million 5mL vial – **1.2** M 10mL vial – **0.2** million

Akovaz™ (ephedrine sulfate injection)

- Indication: Treatment of clinically important hypotension occurring in the setting of anesthesia
- ~ 7 million vials sold annually in the U.S.

** IMS data*

Pediatric Products

Karbinal ER
(carbinoxamine maleate) extended-release oral suspension / 4mg/5mL

- Indication: Perennial allergic rhinitis in children 2 years of age and older
- Patent protection through March 2029
- Rx antihistamine market size in U.S. ~ $110M

CEFACLOR
For Oral Suspension, USP
125 mg/5 mL · 250 mg/5 mL · 375 mg/5 mL

- Indication: 2nd generation Cephalosporin covering a variety of common pathogens
- For children as young as 1 year
- U.S. Market for Cephalosporin ~ $300M

AcipHex® Sprinkle™
(rabeprazole sodium)

- Indication: Treatment of GERD in pediatric patients aged 1-11 years
- Proton Pump Inhibitor (PPI)
- Market size in U.S. ~ $110M

Oflexichamber®
Anti-static Valved Collapsible Holding Chamber Rx Only

- Indication: Collapsible asthma spacer for use with metered dose inhalers (MDIs)
- Patent protection through March 2028
- Market size in U.S. ~ $50M

Strong Intellectual Property

Patent Protection Through..

Platform	US	Europe
Micropump®	July 2027	July 2023
LiquiTime®	September 2025	April 2023
Trigger Lock™	April 2027	May 2026 (pending)
Medusa™	June 2031	June 2027 (pending)

Product	US
Karbinal™ ER	March 2029
Flexichamber®	March 2028

Product specific IP combined with platform IP extend patent life

Seasoned Senior Management

Name	Title	Experience
Michael S. Anderson	**Chief Executive Officer**	40+ years Pharma
Mike Kanan	**Senior Vice President and Chief Financial Officer**	30+ years Financial
Phillandas T. Thompson	**Senior Vice President, General Counsel**	16+ years Legal
Sandy Hatten	**Senior Vice President, Quality and Regulatory Affairs**	30+ years Pharma
Gregory J. Davis	**Vice President, Corporate and Business Development**	20+ years Pharma
David Monteith, Ph.D.	**Vice President, Research and Development**	25+ years Pharma
Dhiren D'Silva	**Vice President of Irish and European Operations**	19+ years Business

Non-GAAP Financial Results

(in $000s) *Reconciliations from GAAP to Non-GAAP can be found in the appendix

	Q3 2016	Q2 2016	Q3 2015	Difference - Inc./(Dec.) Q3 2016 vs. Q2 2016	Difference - Inc./(Dec.) Q3 2016 vs. Q3 2015
Revenue	**$ 32,087**	**$ 38,858**	**$ 47,313**	**$ (6,771)**	**$ (15,226)**
Cost of products and services sold	2,844	3,145	2,087	(301)	757
Research and development expenses	8,143	7,604	7,221	539	922
Selling, general and admin expenses	12,740	11,290	4,568	1,450	8,172
Intangible asset amortization	-	-	-	-	-
Fair value adjustments of contingent consideration	5,884	6,992	9,027	(1,108)	(3,143)
Operating Expenses	29,611	29,031	22,903	580	6,708
Operating income (loss)	**2,476**	**9,827**	**24,410**	**(7,351)**	**(21,934)**
Interest & Other Expense (net)	(559)	(814)	(1,014)	255	455
Income (loss) before income taxes	**1,917**	**9,013**	**23,397**	**(7,096)**	**(21,480)**
Income tax provision	5,416	9,998	10,255	(4,581)	(4,839)
Net loss	**$ (3,499)**	**$ (985)**	**$ 13,142**	**$ (2,515)**	**$ (16,641)**
Diluted loss per share	**$ (0.08)**	**$ (0.02)**	**$ 0.32**	**$ (0.06)**	**$ (0.40)**

Cash Flow Summary

(in $000s)	Nine Months Ended September 30, 2016	2015
TOTAL Cash and Marketable Securities		
Beginning Balance	**$ 144,802**	**$ 92,834**
Operating Cash Flows (excluding tax and earnout/royalty payments)	49,639	92,277
Tax Payments	(22,200)	(34,382)
Earnout/Royalty Payments	(24,229)	(17,655)
Repayment of Debt	-	(4,904)
Issuance of Ordinary Shares and Warrants	-	6,990
FX & Other, net	1,655	(6,788)
Change in Total	**4,865**	**35,538**
Ending Balance	**$ 149,667**	**$ 128,372**

Balance sheet remains strong with no bank debt and $149.7 million in cash and marketable securities

Company Highlights

Strong Financial Position	• Cash flow positive & strong balance sheet – NO DEBT • $154.9 million in cash and marketable securities as of June 30, 2016
Phase III Trial	• Data for Micropump® applied to sodium oxybate expected 1H 2018 • Current market size in excess of $1 billion
Expanding Product Portfolio	• 3 branded hospital products with little competition • 4 products added through acquisition of FSC Pediatrics in Q1 2016
Platform Technologies	• Micropump® sodium oxybate • LiquiTime® for OTC and Rx • Trigger Lock™ hydromorphone • Medusa™ exenatide
Extensive IP	• Technology patent life extends to a minimum of 2025 • Product specific IP will extend patent life

Mission: Build a diversified specialty pharmaceutical company that controls 100% of its drug development and future

Appendix

GAAP to Non-GAAP Reconciliations

Three Months Ended September 30, 2016:

(in thousands - USD$)

		Adjustments				
		Exclude			Include	
	GAAP	Intangible asset amortization	Foreign exchange (gain)/loss	Contingent related party payable fair value remeasurements	Contingent related party payable paid/accrued	Total Adjustments	NON-GAAP
Product sales and services	$ 31,340	$ -	$ -	$ -	$ -	$ -	$ 31,340
License and research revenue	*747*	-	-	-	-	-	*747*
Total revenue	**32,087**	**-**	**-**	**-**	**-**	**-**	**32,087**
Cost of products and services sold (3rd Party)	2,844	-	-	-	-	-	2,844
Intercompany cost of products sold	-	-	-	-	-	-	-
Cost of products and services sold	2,844	-	-	-	-	-	2,844
Research and development expenses	8,143	-	-	-	-	-	8,143
Selling, general and administrative expenses	12,740	-	-	-	-	-	12,740
Intangible asset amortization	3,702	(3,702)	-	-	-	(3,702)	-
Changes in fair value of related party contingent consideration	20,848	-	-	(20,848)	5,884	(14,964)	5,884
Total operating expenses	**48,277**	**(3,702)**	**-**	**(20,848)**	**5,884**	**(18,666)**	**29,611**
Operating income (loss)	**(16,190)**	**3,702**	**-**	**20,848**	**(5,884)**	**18,666**	**2,476**
Investment Income	490	-	-	-	-	-	490
Interest Expense	(264)	-	-	-	-	-	(264)
Other Expense - changes in fair value of related party payable	(1,828)	-	-	1,828	(785)	1,043	(785)
Foreign exchange gain (loss)	1,249	-	(1,249)	-	-	(1,249)	-
Income (loss) before income taxes	**(16,543)**	**3,702**	**(1,249)**	**22,676**	**(6,669)**	**18,460**	**1,917**
Income tax provision	3,451	1,329	-	1,021	(385)	1,965	5,416
Income Tax Rate	*(21%)*	*36%*	-	*5%*	*6%*	*11%*	*283%*
Net Loss	**$ (19,994)**	**$ 2,373**	**$ (1,249)**	**$ 21,655**	**$ (6,284)**	**$ 16,495**	**$ (3,499)**
Net loss per share - Diluted	**$ (0.48)**	**$ 0.06**	**$ (0.03)**	**$ 0.52**	**$ (0.15)**	**$ 0.40**	**$ (0.08)**
Weighted average number of shares outstanding - Diluted	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*

GAAP to Non-GAAP Reconciliations

Three Months Ended June 30, 2016:

(in thousands - USD$)

		Adjustments						
		Exclude				Include		
	GAAP	Intangible asset amortization	Foreign exchange (gain)/loss	Purchase accounting adjustments - FSC	Contingent related party payable fair value remeasurements	Contingent related party payable paid/accrued	Total Adjustments	NON-GAAP
Product sales and services	$ 38,165	$ -	$ -	$ -	$ -	$ -	$ -	$ 38,165
License and research revenue	*693*	-	-	-	-	-	-	*693*
Total revenue	**38,858**	**-**	**-**	**-**	**-**	**-**	**-**	**38,858**
Cost of products and services sold	3,907	-	-	(762)	-	-	(762)	3,145
Research and development expenses	7,604	-	-	-	-	-	-	7,604
Selling, general and administrative expenses	11,290	-	-	-	-	-	-	11,290
Intangible asset amortization	3,702	(3,702)	-	-	-	-	(3,702)	-
Changes in fair value of related party contingent consideration	23,898	-	-	-	(23,898)	6,992	(16,906)	6,992
Total operating expenses	**50,401**	**(3,702)**	**-**	**(762)**	**(23,898)**	**6,992**	**(21,370)**	**29,031**
Operating income (loss)	**(11,543)**	**3,702**	**-**	**762**	**23,898**	**(6,992)**	**21,370**	**9,827**
Investment Income	390	-	-	-	-	-	-	390
Interest Expense	(263)	-	-	-	-	-	-	(263)
Other Expense - changes in fair value of related party payable	(2,773)	-	-	-	2,773	(941)	1,832	(941)
Foreign exchange gain (loss)	1,680	-	(1,680)	-	-	-	(1,680)	-
Income (loss) before income taxes	**(12,509)**	**3,702**	**(1,680)**	**762**	**26,671**	**(7,933)**	**21,522**	**9,013**
Income tax provision	7,449	1,329	-	266	1,414	(460)	2,549	9,998
Income Tax Rate	*(60%)*	*36%*	*-*	*35%*	*5%*	*6%*	*12%*	*111%*
Net Loss	**$ (19,958)**	**$ 2,373**	**$ (1,680)**	**$ 496**	**$ 25,257**	**$ (7,473)**	**$ 18,973**	**$ (985)**
Net loss per share - Diluted	**$ (0.48)**	**$ 0.06**	**$ (0.04)**	**$ 0.01**	**$ 0.60**	**$ (0.18)**	**$ 0.46**	**$ (0.02)**
Weighted average number of shares outstanding - Diluted	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*	*41,241*

GAAP to Non-GAAP Reconciliations

Three Months Ended September 30, 2015:

(in thousands - USD$)

		Adjustments					
		Exclude			Include		
	GAAP	Intangible asset amortization	Foreign exchange (gain)/loss	Contingent related party payable fair value remeasurements	Contingent related party payable paid/accrued	Total Adjustments	NON-GAAP
Product sales and services	$ 47,313	$ -	$ -	$ -	$ -	$ -	$ 47,313
License and research revenue	-	-	-	-	-	-	-
Total revenue	**47,313**	**-**	**-**	**-**	**-**	**-**	**47,313**
Cost of products and services sold	2,087	-	-	-	-	-	2,087
Research and development expenses	7,221	-	-	-	-	-	7,221
Selling, general and administrative expenses	4,568	-	-	-	-	-	4,568
Intangible asset amortization	3,141	(3,141)	-	-	-	(3,141)	-
Changes in fair value of related party contingent consideration	44,782	-	-	(44,782)	9,027	(35,755)	9,027
Total operating expenses	**61,799**	**(3,141)**	**-**	**(44,782)**	**9,027**	**(38,896)**	**22,903**
Operating income (loss)	**(14,486)**	**3,141**	**-**	**44,782**	**(9,027)**	**38,896**	**24,410**
Investment Income	197	-	-	-	-	-	197
Interest Expense	-	-	-	-	-	-	-
Other Expense - changes in fair value of related party payable	(6,644)	-	-	6,644	(1,211)	5,433	(1,211)
Foreign exchange gain (loss)	160	-	(160)	-	-	(160)	-
Income (loss) before income taxes	**(20,773)**	**3,141**	**(160)**	**51,426**	**(10,237)**	**44,170**	**23,397**
Income tax provision	7,302	1,099	(48)	2,325	(424)	2,953	10,255
Income Tax Rate	*(35%)*	*35%*	*30%*	*5%*	*4%*	*7%*	*44%*
Net Loss	**$ (28,075)**	**$ 2,042**	**$ (112)**	**$ 49,101**	**$ (9,814)**	**$ 41,217**	**$ 13,142**
Net loss per share - Diluted	**$ (0.69)**	**$ 0.05**	**$ -**	**$ 1.20**	**$ (0.24)**	**$ 1.01**	**$ 0.32**
Weighted average number of shares outstanding - Diluted	*40,625*	*40,625*	*40,625*	*40,625*	*40,625*	*40,625*	*40,625*

Flamel's Proprietary Drug Delivery Platforms

Advanced Formulation and Delivery Platforms for Better and Safer Drugs



Micropump®
Drug Delivery Platform

Modified/Controlled Release of Solid Oral Drugs

Micropump®

Micropump® allows development of modified and/or controlled release of solid, oral dosage formulations of drugs

- Derivative **LiquiTime®** allows development of modified/controlled release of liquid formulations
- Derivative **Trigger Lock™** allows development of tamper-resistant modified/controlled release formulations of narcotic/opioid analgesics

Versatility of Micropump® allows development of differentiated product profiles (SR / DR formulations) under various dosage forms:

- Capsules, tablets, sachets (sodium oxybate)
- Oral liquid suspensions (LiquiTime®)

Unique formulation used for different dose strengths and forms

- Same drug with different release profiles or
- Two or more drugs with tailored release profiles for combination therapy



Micropump® Platform at a Glance

- Extended/delayed release of drugs throughout GI Tract
- Precise pharmacokinetics of single or combination drugs in various formats
- Numerous Micropump®-based products have been successfully tested in human clinical trials



Microparticles for Controlled/Modified Release



- Microparticles dispersed in the stomach, pass into the small intestine where each microparticle releases drug at an adjustable rate over an extended period of time (up to 24 hours)
- Drug released at adjustable rate controlled (time dependent release: SR coating) and/or delayed (pH and time dependent release: DR coating)
- Micropump® microparticles can be used separately or together to provide highly specialized delivery profiles

LiquiTime®
Drug Delivery Platform

Modified/Controlled Release of Liquid Oral Drugs

LiquiTime®

- Allows development of modified/controlled release liquid formulations for patients having issues swallowing tablets/capsules
- **Not limited to working solely with ionic drugs as with resin-complex based technologies**
- Readily scalable to commercial quantities
- Easy to swallow, good mouth feel, taste masked - dose flexibility while maintaining accuracy and safety

Applicable to:

Pediatric[1]

- US population younger than 18 years old = 76 million in 2019
- 75% of households with children under 12 purchased an OTC pain reliever over the past 12 months
- Sales of OTC pediatric product in the US = $1.6 B in 2013 ($1.9 B estimated in 2018)

Geriatric

- 810 million people > 60 years in 2012 2 billion expected in 2050[2]
- In 2010 approximately 45-50% of the prescriptions were written for people aged 60 and above and one in three patients took at least 5 drugs or more on a daily basis in the United States[3]

[1] "OTC Pediatrics – US" (March 2014, Mintel) *[2] World Health Organization*

[3] "Geriatric Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019" (Transparency Market Research)



Trigger Lock™ Platform

Abuse Deterrent Extended Release of Opioids

Trigger Lock™ for Abuse Deterrence

- **Drug loaded Micropump® microparticles:** Sustained Release (SR) microparticles individually polymer coated which are resistant to crushing
- **Viscosifying ingredient(s):** To prevent abuse by injection after extraction in a small volume of solvent
- **Quenching ingredient(s):** To prevent extraction in large volumes of liquid (forming a complex with the opioid preventing its solubilization in aqueous/alcoholic media)

➔ **Each microparticle retains its polymer coating**

➔ **Trigger Lock™ is virtually impervious to crushing**

Medusa™ Drug Delivery Platform

Modified/Controlled Release of Injectable Drugs

In Vivo Drug Release from Medusa™ Depot